Cullinan Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-219.9M | $-167.4M | $-153.2M | $111.2M | $-65.6M | $-51.8M |
| Depreciation & Amortization | $311.0K | $306.0K | $310.0K | $93.0K | $53.0K | $62.0K |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $36.0M | $37.8M | $30.4M | $28.0M | $24.4M | $14.9M |
| Net Cash from Operating Activities | $-175.8M | $-145.3M | $-134.3M | $-126.7M | $-43.4M | $-29.8M |
| Investing Activities | ||||||
| Capital Expenditures | $49.0K | $0 | $208.0K | $1.1M | $0 | $10.0K |
| Business Acquisitions | — | — | — | — | — | $-1.5M |
| Net Cash from Investing Activities | $180.0M | $-136.3M | $35.8M | $249.0M | $-333.8M | $-5.4M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | $6.6M |
| Net Cash from Financing Activities | $1.1M | $266.2M | $40.8M | $-25.9M | $268.8M | $140.1M |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | $-175.8M | $-145.3M | $-134.5M | $-127.8M | $-43.4M | $-29.8M |